Showing 2211-2220 of 4944 results for "".
- Positive Top-line Results Seen in Pivotal Phase 3 Clinical Trial of StrataGraft Regenerative Tissue Deep Partial-thickness Thermal Burnshttps://practicaldermatology.com/news/positive-top-line-results-seen-in-pivotal-phase-3-clinical-trial-of-stratagraft-regenerative-tissue-deep-partial-thickness-thermal-burns/2460178/Mallinckrodt plc's pivotal Phase 3 clinical trial evaluating the efficacy and safety of a single application of StrataGraft regenerative tissue in the treatment of deep partial-thickness thermal burns met both primary endpoints. The pivotal open-label, controlled, randomized, multic
- Above-the-Neck Melanoma More Likely to Spreadhttps://practicaldermatology.com/news/above-the-neck-melanoma-more-likely-to-spread/2460176/Malignant melanoma above the neck is more likely to spread, according to new findings presented at the 28th European Dermato-Venereology Society Congress in Madrid. New results from a descriptive, 6-month clinical study suggest that malignant melanoma that develops on the ne
- Research Substantiates Psoriasis/Non-alcoholic Fatty Liver Disease Linkhttps://practicaldermatology.com/news/research-substantiates-psoriasisnon-alcoholic-fatty-liver-disease-link/2460174/The severity of psoriasis is related to the severity of non-alcoholic fatty liver disease (NAFLD), according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. Patients with psoriasis and NAFLD had more severe hepatic damage if they had a higher s
- Positive Phase 2 Results Seen With Galderma’s Proprietary Liquid Toxin for Frown Lineshttps://practicaldermatology.com/news/positive-phase-2-results-seen-with-galdermas-proprietary-liquid-toxin-for-frown-lines-2/2460170/Galderma’s novel liquid abotulinum toxin, QM1114, is safe and effective for the treatment of glabellar lines, according to Phase 2 study results. Pivotal Phase 3 trials for Galderma's liquid formulation of botulinum toxin type A for the treatment of glabellar lines are expecte
- It's Grant Time: La Fondation La Roche-Posay Calls for Scientific Abstractshttps://practicaldermatology.com/news/its-grant-time-la-fondation-la-roche-posay-calls-for-scientific-abstracts/2460169/Calling all residents, fellows, and practitioners within their first five years of practice: La Fondation La Roche-Posay (North American) is now accepting submissions for their 2020 grants program. Three grants for $10,000, $5,000 & $5,000 will be awarded for innovative program
- La Roche-Posay Foundation Opens Call for Abstractshttps://practicaldermatology.com/news/la-roche-posay-foundation-opens-call-for-abstracts/2460163/The La Roche-Posay North American Foundation has opened a call for scientific abstracts. The La Roche-Posay North American Foundation was established in 2005 to support outstanding candidates with promising projects in the field of clinical, biological or pharmacological research linked to
- With New Funding, Turn Therapeutics Will Launch Phase 4 Study of AD Drughttps://practicaldermatology.com/news/with-new-funding-turn-therapeutics-will-launch-phase-4-study-of-ad-drug/2460162/Turn Therapeutics has closed its fully-subscribed series B financing. The capital raised will fund a large-scale, pre-launch, phase 4 trial for AtopX Eczema Emulsion, with enrollment scheduled to begin in Q1 2020. The series B financing will also support advancement of additional i
- Positive Top Line Results from Second Phase 3 Study of Abrocitinib for Atopic Dermatitishttps://practicaldermatology.com/news/positive-top-line-results-from-second-phase-3-study-of-abrocitinib-for-atopic-dermatitis-1/2460159/Pfizer Inc. shared positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherap
- Study: Long-Term Use of Brodalumab Is Safe, Effectivehttps://practicaldermatology.com/news/study-long-term-use-of-brodalumab-is-safe-effective/2460150/Long-term use of brodalumab (SILIQ) improved skin clearance and quality of life in patients with moderate-to-severe psoriasis, according to a new study in the American Journal of Clinical Dermatology. Ov
- Skin Cancer Foundation Website Has a New Lookhttps://practicaldermatology.com/news/skin-cancer-foundation-website-has-a-new-look/2460148/The Skin Cancer Foundation’s website has a new look. The site is redesigned to ease navigation and provide visitors with an improved user experience. Nearly 9 million people visit SkinCancer.org annually, and the organization say